Coronavirus (COVID-19)

• Ritonavir-Boosted Nirmatrelvir Prescribing Information
• Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Medications
• The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
• The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
• Vaccines and therapeutics for immunocompromised patients with COVID-19
• Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
• The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
• Long COVID: major findings, mechanisms and recommendations
• Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
• The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
• CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
• IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
• Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
• COVID-19 Drug Interactions
• Dexamethasone in Hospitalized Patients with Covid-19
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19
• Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
• Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
• Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
• NIH COVID-19 Treatment Guidelines
• FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
• Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
• Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
• Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
• CDC Coronavirus Disease 2019 (COVID-19) Resources
• WHO Resources: COVID-19 Pandemic
• Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
• Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
• JAMA Patient Page: Oral antiviral medications for COVID-19
• Molnupiravir EUA
• Nirmatrelvir EUA

Gram-negative Bacterial Infections

• Gram-negative Bacteria Infections in Healthcare Settings
• IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
• Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
• New Perspectives on Antimicrobial Agents: Cefiderocol

Cytomegalovirus (CMV)

• Letermovir for Secondary Prophylaxis of CMV Infection
• Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
• Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
• Cytomegalovirus (CMV) Infection
• About CMV for Patients
• Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients

Herpes Zoster

• What You Can Expect After Getting Shingrix Vaccine Fact Sheet

HIV

• Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
• INSTI Drug Interactions
• HIV and Drug-resistance Testing
• Evidence-based Interventions to Improve HIV Medication Adherence
• Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
• Adherence to the Continuum of Care
• Drug-Drug Interactions
• Drug Database: Cabotegravir
• Women with HIV
• Adverse Effects of Antiretroviral Therapy
• Considerations for Antiretroviral Therapy in the Older Patient
• Stanford University HIV Drug Resistance Database
• Understanding HIV Laboratory Tests – for Patients
• NNRTI Drug Interactions
• NRTI Drug Interactions
• PI Drug Interactions
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
• What to Start: Selecting a First HIV Regimen

PrEP

• Patient/Clinician Handout: PrEP 2-1-1
• HIV PrEP With FTC/TDF Among Cisgender Women
• Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
• Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
• Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
• Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
• PrEP Resources in all 50 States
• National Clinician Consultation Center for PrEP
• Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
• Quick Guide: 2021 PrEP Update
• Pre-Exposure Prophylaxis (PrEP)
• HIV Prevention Materials for Your Practice
• Let’s Stop HIV Together: HIV Prevention
• Drug information on cabotegravir
• Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
• Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084

Influenza

• Influenza Antiviral Drug Resistance
• A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
• Seasonal Influenza Vaccine Effectiveness Studies
• Influenza Antiviral Medications: Summary for Clinicians
• FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
• Information for Clinicians on Influenza Virus Testing
• What You Should Know About Influenza (Flu) Antiviral Drugs
• People at High Risk For Flu Complications
• Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
• Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
• Similarities and Differences between Flu and COVID-19

Invasive Fungal Infections

• CDC Fungal Diseases – Patient Information
• Information for Healthcare Professionals about Invasive Candidiasis
• Information for Healthcare Professionals about Mucormycosis
• Information for Healthcare Professionals about Aspergillosis

Molecular Diagnostics

• Panels and Syndromic Testing in Clinical Microbiology
• Advances in rapid diagnostics for bloodstream infections
• Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis
• Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables
• Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

Pediatrics

• Recommendations for Prevention and Control of Influenza in Children, 2022–2023
• Cryptosporidiosis
• Giardiasis
• Swimming Pool Hygiene
• Facts About Crypto and Swimming Pools – Patient Handout
• Human Papillomavirus (HPV): The Need to Immunize – Patient Handout

Pneumococcal Disease

• Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
• Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
• Updated ACIP Recommendations and Evidence Review: Use of PCV15 and PCV20 Among US Adults
• Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
• Pneumococcal Vaccination
• AAFP: Simplifying Pneumococcal Immunizations for Adults
• Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
• Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
• PneumoRecs VaxAdvisor Mobile App
• Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
• PCV15 Prescribing Information
• PCV20 Prescribing Information

Respiratory Syncytial Virus (RSV)

• RSV surges early in 2022, but appears to make early retreat
• Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season
• Multiple RSV vaccines in late-stage development show promise in older adults
• CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
• Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
• A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
• Respiratory Syncytial Virus (RSV)
• CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
• Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
• Respiratory Syncytial Virus Infection